Table S2 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Year: 2023
Type: other
Abstract: Table S2. Demographic and clinical characteristics of 30 cancer patients with mTOR pathway mutations. S2.1. Master table showing a summary of demographic characteristics and clinical outcomes. S2.2. Prior systemic treatment regimens. S2.3. Objective response to everolimus according to RECIST v1.1 criteria. S2.4. Toxicity profile of patients according to CTCAE v4.0.
Authors: Elio Adib, Katarzyna Klonowska, Krinio Giannikou, Khanh T. Do, Solida Pruitt-Thompson, Ketki Bhushan, Matthew I. Milstein, Jennifer Hedglin, Katherine E. Kargus, Lynette M. Sholl, Junko Tsuji, David M. Hyman, Anne Sisk, Geoffrey I. Shapiro, Hebert A. Vargas, James J. Harding, Martin H. Voss, Gopa Iyer, David J. Kwiatkowski
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362419183